Skip to main content
Top
Published in: Endocrine 1/2013

01-02-2013 | Original Article

Altered gene expression involved in insulin signaling pathway in type II diabetic osteoporosis rats model

Authors: Baoxin Li, Yan Wang, Yan Liu, Jianxia Ma, Yukun Li

Published in: Endocrine | Issue 1/2013

Login to get access

Abstract

It is well established that both estrogen loss and type II diabetes mellitus (DMII) can impair bone metabolism, but whether estrogen loss exacerbates the effects of DMII is unclear. Therefore, we determined if ovariectomy (OVX) of rats on a long-term high-fat/sugar diet and injection of a low dose of streptozotocin (DMII) decreased bone mineral density (BMD) more than OVX or DMII alone. Bone insulin signaling is known to support bone metabolism; therefore, we also tested the hypothesis that OVX DMII rats (DOVX) would exhibit greater reductions in the expression of proteins important in insulin signaling, including IRS-1, IRS-2, and IGF-1. As hypothesized, BMD and plasma estrogen levels were decreased more in DOVX rats than in rats following OVX (NOVX) or DMII (DS) alone. IGF-1 expression was decreased in the liver, kidney, skeletal muscle, and bone of DOVX, DS, and NOVX rats; however, the decrease was larger and occurred sooner in DOVX rats. While IRS-1 and IRS-2 decreased in most groups in all tissues examined, the expression patterns differed in both a group- and tissue-dependent fashion. In conclusion, these data demonstrate that estrogen loss and DMII induced by a high-fat/sugar diet interact to produce osteoporosis and support the hypothesis that the bone loss may be mediated at least in part by concurrent decreases in the insulin signaling proteins in bone.
Literature
1.
go back to reference M. Prasannarong, K. Vichaiwong, V. Saengsirisuwan, Calorie restriction prevents the development of insulin resistance and impaired insulin signaling in skeletal muscle of ovariectomized rats. Biochim. Biophys. Acta 1822, 1051–1061 (2012)PubMedCrossRef M. Prasannarong, K. Vichaiwong, V. Saengsirisuwan, Calorie restriction prevents the development of insulin resistance and impaired insulin signaling in skeletal muscle of ovariectomized rats. Biochim. Biophys. Acta 1822, 1051–1061 (2012)PubMedCrossRef
2.
go back to reference D. Unal, S. Aksak, Z. Halici, O. Sengul, B. Polat, B. Unal, M. Halici, Effects of diabetes mellitus on the rat liver during the postmenopausal period. J. Mol. Histol. 42, 273–287 (2011)PubMedCrossRef D. Unal, S. Aksak, Z. Halici, O. Sengul, B. Polat, B. Unal, M. Halici, Effects of diabetes mellitus on the rat liver during the postmenopausal period. J. Mol. Histol. 42, 273–287 (2011)PubMedCrossRef
3.
go back to reference H. Chang-Quan, D. Bi-Rong, H. Ping, L. Zhen-Chan, Insufficient renal 1-alpha hydroxylase and bone homeostasis in aged rats with insulin resistance or type 2 diabetes mellitus. J. Bone. Miner. Metab. 26, 561–568 (2008)PubMedCrossRef H. Chang-Quan, D. Bi-Rong, H. Ping, L. Zhen-Chan, Insufficient renal 1-alpha hydroxylase and bone homeostasis in aged rats with insulin resistance or type 2 diabetes mellitus. J. Bone. Miner. Metab. 26, 561–568 (2008)PubMedCrossRef
4.
go back to reference S. Elis, H.W. Courtland, Y. Wu, J.C. Fritton, H. Sun, C.J. Rosen, S. Yakar, Elevated serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis is intact. J. Bone. Miner. Res. 25, 2051–2058 (2010)PubMedCrossRef S. Elis, H.W. Courtland, Y. Wu, J.C. Fritton, H. Sun, C.J. Rosen, S. Yakar, Elevated serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis is intact. J. Bone. Miner. Res. 25, 2051–2058 (2010)PubMedCrossRef
5.
go back to reference R. Blakytny, M. Spraul, E.B. Jude, Review: the diabetic bone: a cellular and molecular perspective. Int. J. Low. Extrem. Wounds 10, 16–32 (2011)PubMedCrossRef R. Blakytny, M. Spraul, E.B. Jude, Review: the diabetic bone: a cellular and molecular perspective. Int. J. Low. Extrem. Wounds 10, 16–32 (2011)PubMedCrossRef
6.
go back to reference T.D. Rachner, S. Khosla, L.C. Hofbauer, Osteoporosis: now and the future. Lancet 377, 1276–1287 (2011)PubMedCrossRef T.D. Rachner, S. Khosla, L.C. Hofbauer, Osteoporosis: now and the future. Lancet 377, 1276–1287 (2011)PubMedCrossRef
7.
go back to reference G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41, 58–69 (2012)PubMedCrossRef G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41, 58–69 (2012)PubMedCrossRef
8.
go back to reference F.J. de Paula, M.C. Horowitz, C.J. Rosen, Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab. Res. Rev. 26, 622–630 (2010)PubMedCrossRef F.J. de Paula, M.C. Horowitz, C.J. Rosen, Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab. Res. Rev. 26, 622–630 (2010)PubMedCrossRef
9.
go back to reference S. Kurra, E. Siris, Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures. Diabetes Metab. Res. Rev. 27, 430–435 (2011)PubMedCrossRef S. Kurra, E. Siris, Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures. Diabetes Metab. Res. Rev. 27, 430–435 (2011)PubMedCrossRef
10.
go back to reference C. Torti, G. Mazziotti, P.A. Soldini, E. Focà, R. Maroldi, D. Gotti, G. Carosi, A. Giustina, High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41, 512–517 (2012)PubMedCrossRef C. Torti, G. Mazziotti, P.A. Soldini, E. Focà, R. Maroldi, D. Gotti, G. Carosi, A. Giustina, High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41, 512–517 (2012)PubMedCrossRef
11.
go back to reference S. Perrini, A. Natalicchio, L. Laviola, A. Cignarelli, M. Melchiorre, F. De Stefano, C. Caccioppoli, A. Leonardini, S. Martemucci, G. Belsanti, S. Miccoli, A. Ciampolillo, A. Corrado, F.P. Cantatore, R. Giorgino, F. Giorgino, Abnormalities of insulin-like growth factor-I signaling and impaired cell proliferation in osteoblasts from subjects with osteoporosis. Endocrinology 149, 1302–1313 (2008)PubMedCrossRef S. Perrini, A. Natalicchio, L. Laviola, A. Cignarelli, M. Melchiorre, F. De Stefano, C. Caccioppoli, A. Leonardini, S. Martemucci, G. Belsanti, S. Miccoli, A. Ciampolillo, A. Corrado, F.P. Cantatore, R. Giorgino, F. Giorgino, Abnormalities of insulin-like growth factor-I signaling and impaired cell proliferation in osteoblasts from subjects with osteoporosis. Endocrinology 149, 1302–1313 (2008)PubMedCrossRef
12.
go back to reference A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–559 (2008)PubMedCrossRef A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–559 (2008)PubMedCrossRef
13.
go back to reference J. Paccou, J. Dewailly, B. Cortet, Reduced levels of serum IGF-1 is related to the presence of osteoporotic fractures in male idiopathic osteoporosis. Joint Bone Spine 79, 78–82 (2012)PubMedCrossRef J. Paccou, J. Dewailly, B. Cortet, Reduced levels of serum IGF-1 is related to the presence of osteoporotic fractures in male idiopathic osteoporosis. Joint Bone Spine 79, 78–82 (2012)PubMedCrossRef
14.
15.
go back to reference R.A. Soslow, A.J. Dannenberg, D. Rush, B.M. Woerner, K.N. Khan, J. Masferrer, A.T. Koki, COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89, 2637–2645 (2000)PubMedCrossRef R.A. Soslow, A.J. Dannenberg, D. Rush, B.M. Woerner, K.N. Khan, J. Masferrer, A.T. Koki, COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89, 2637–2645 (2000)PubMedCrossRef
16.
go back to reference R.R. Bosch, S.W. Janssen, P.N. Span, A. Olthaar, S.E. van Emst-de Vries, P.H. Willems, J.M.G. Martens, A.R. Hermus, C.C. Sweep, Exploring levels of hexosamine biosynthesis pathway intermediates and protein kinase C isoforms in muscle and fat tissue of Zucker diabetic fatty rats. Endocrine 20, 247–252 (2003)PubMedCrossRef R.R. Bosch, S.W. Janssen, P.N. Span, A. Olthaar, S.E. van Emst-de Vries, P.H. Willems, J.M.G. Martens, A.R. Hermus, C.C. Sweep, Exploring levels of hexosamine biosynthesis pathway intermediates and protein kinase C isoforms in muscle and fat tissue of Zucker diabetic fatty rats. Endocrine 20, 247–252 (2003)PubMedCrossRef
17.
go back to reference M. Mansour, D. White, C. Wernette, J. Dennis, Y.X. Tao, R. Collins, L. Parker, E. Morrison, Pancreatic neuronal melanocortin-4 receptor modulates serum insulin levels independent of leptin receptor. Endocrine 37, 220–230 (2010)PubMedCrossRef M. Mansour, D. White, C. Wernette, J. Dennis, Y.X. Tao, R. Collins, L. Parker, E. Morrison, Pancreatic neuronal melanocortin-4 receptor modulates serum insulin levels independent of leptin receptor. Endocrine 37, 220–230 (2010)PubMedCrossRef
18.
go back to reference M.H. Giroix, K. Louchami, Y.A. Carpentier, A. Sener, W.J. Malaisse, Fatty acid pattern of pancreatic islet lipids in Goto–Kakizaki rats. Endocrine 37, 173–179 (2010)PubMedCrossRef M.H. Giroix, K. Louchami, Y.A. Carpentier, A. Sener, W.J. Malaisse, Fatty acid pattern of pancreatic islet lipids in Goto–Kakizaki rats. Endocrine 37, 173–179 (2010)PubMedCrossRef
19.
go back to reference M. Matsushita, K. Tamura, S. Osada, H. Kogo, Effect of troglitazone on the excess testosterone and LH secretion in thyroidectomized, insulin-resistant, type 2 diabetic Goto–Kakizaki rats. Endocrine 27, 301–305 (2005)PubMedCrossRef M. Matsushita, K. Tamura, S. Osada, H. Kogo, Effect of troglitazone on the excess testosterone and LH secretion in thyroidectomized, insulin-resistant, type 2 diabetic Goto–Kakizaki rats. Endocrine 27, 301–305 (2005)PubMedCrossRef
20.
go back to reference M.S. Islam, T. Loots du, Experimental rodent models of type 2 diabetes: a review. Methods Find. Exp. Clin. Pharmacol. 31, 249–261 (2009)PubMed M.S. Islam, T. Loots du, Experimental rodent models of type 2 diabetes: a review. Methods Find. Exp. Clin. Pharmacol. 31, 249–261 (2009)PubMed
21.
go back to reference M. Yu, W. Zhou, Y. Song, F. Yu, D. Li, S. Na, G. Zou, M. Zhai, C. Xie, Development of mesenchymal stem cell-implant complexes by cultured cells sheet enhances osseointegration in type 2 diabetic rat model. Bone 49, 387–394 (2011)PubMedCrossRef M. Yu, W. Zhou, Y. Song, F. Yu, D. Li, S. Na, G. Zou, M. Zhai, C. Xie, Development of mesenchymal stem cell-implant complexes by cultured cells sheet enhances osseointegration in type 2 diabetic rat model. Bone 49, 387–394 (2011)PubMedCrossRef
22.
go back to reference K. Srinivasan, B. Viswanad, L. Asrat, C.L. Kaul, P. Ramarao, Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 52, 313–320 (2005)PubMedCrossRef K. Srinivasan, B. Viswanad, L. Asrat, C.L. Kaul, P. Ramarao, Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 52, 313–320 (2005)PubMedCrossRef
23.
go back to reference M.J. Reed, K. Meszaros, L.J. Entes, M.D. Claypool, J.G. Pinkett, T.M. Gadbois, G.M. Reaven, A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 49, 1390–1394 (2000)PubMedCrossRef M.J. Reed, K. Meszaros, L.J. Entes, M.D. Claypool, J.G. Pinkett, T.M. Gadbois, G.M. Reaven, A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 49, 1390–1394 (2000)PubMedCrossRef
24.
go back to reference W. Sun, Y. Bi, H. Liang, M. Cai, X. Chen, Y. Zhu, M. Li, F. Xu, Q. Yu, X. He, J. Ye, J. Weng, Inhibition of obesity-induced hepatic ER stress by early insulin therapy in obese diabetic rats. Endocrine 39, 235–241 (2011)PubMedCrossRef W. Sun, Y. Bi, H. Liang, M. Cai, X. Chen, Y. Zhu, M. Li, F. Xu, Q. Yu, X. He, J. Ye, J. Weng, Inhibition of obesity-induced hepatic ER stress by early insulin therapy in obese diabetic rats. Endocrine 39, 235–241 (2011)PubMedCrossRef
25.
go back to reference D. Merlotti, L. Gennari, F. Dotta, D. Lauro, R. Nuti, Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 20, 683–690 (2010)PubMedCrossRef D. Merlotti, L. Gennari, F. Dotta, D. Lauro, R. Nuti, Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 20, 683–690 (2010)PubMedCrossRef
26.
go back to reference R.A. Kayal, J. Alblowi, E. McKenzie, N. Krothapalli, L. Silkman, L. Gerstenfeld, T.A. Einhorn, D.T. Graves, Diabetes causes the accelerated loss of cartilage during fracture repair which is reversed by insulin treatment. Bone 44, 357–363 (2009)PubMedCrossRef R.A. Kayal, J. Alblowi, E. McKenzie, N. Krothapalli, L. Silkman, L. Gerstenfeld, T.A. Einhorn, D.T. Graves, Diabetes causes the accelerated loss of cartilage during fracture repair which is reversed by insulin treatment. Bone 44, 357–363 (2009)PubMedCrossRef
27.
go back to reference A. Montagnani, S. Gonnelli, M. Alessandri, R. Nuti, Osteoporosis and risk of fracture in patients with diabetes: an update. Aging Clin. Exp. Res. 23, 84–90 (2011)PubMed A. Montagnani, S. Gonnelli, M. Alessandri, R. Nuti, Osteoporosis and risk of fracture in patients with diabetes: an update. Aging Clin. Exp. Res. 23, 84–90 (2011)PubMed
28.
go back to reference J.M. Pritchard, L.M. Giangregorio, S.A. Atkinson, K.A. Beattie, D. Inglis, G. Ioannidis, Z. Punthakee, J.D. Adachi, A. Papaioannou, Adults with type 2 diabetes mellitus (DM) have an elevated fracture risk despite normal areal bone mineral density (aBMD). Arthr. Care Res. (Hoboken) 64, 83–91 (2012)CrossRef J.M. Pritchard, L.M. Giangregorio, S.A. Atkinson, K.A. Beattie, D. Inglis, G. Ioannidis, Z. Punthakee, J.D. Adachi, A. Papaioannou, Adults with type 2 diabetes mellitus (DM) have an elevated fracture risk despite normal areal bone mineral density (aBMD). Arthr. Care Res. (Hoboken) 64, 83–91 (2012)CrossRef
29.
go back to reference T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi, A. Giustina, Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 45, 784–788 (2009)PubMedCrossRef T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi, A. Giustina, Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 45, 784–788 (2009)PubMedCrossRef
30.
go back to reference G. Mazziotti, M. Gola, A. Bianchi, T. Porcelli, A. Giampietro, V. Cimino, M. Doga, C. Gazzaruso, L. De Marinis, A. Giustina, Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 40, 102–108 (2011)PubMedCrossRef G. Mazziotti, M. Gola, A. Bianchi, T. Porcelli, A. Giampietro, V. Cimino, M. Doga, C. Gazzaruso, L. De Marinis, A. Giustina, Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 40, 102–108 (2011)PubMedCrossRef
31.
go back to reference A. Shu, M.T. Yin, E. Stein, S. Cremers, E. Dworakowski, R. Ives, M.R. Rubin, Bone structure and turnover in type 2 diabetes mellitus. Osteoporos. Int. 23, 635–641 (2012)PubMedCrossRef A. Shu, M.T. Yin, E. Stein, S. Cremers, E. Dworakowski, R. Ives, M.R. Rubin, Bone structure and turnover in type 2 diabetes mellitus. Osteoporos. Int. 23, 635–641 (2012)PubMedCrossRef
32.
go back to reference C. Hamann, C. Goettsch, J. Mettelsiefen, V. Henkenjohann, M. Rauner, U. Hempel, R. Bernhardt, N. Fratzl-Zelman, P. Roschger, S. Rammelt, K.P. Günther, L.C. Hofbauer, Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. Am. J. Physiol. Endocrinol. Metab. 301, E1220–E1228 (2011)PubMedCrossRef C. Hamann, C. Goettsch, J. Mettelsiefen, V. Henkenjohann, M. Rauner, U. Hempel, R. Bernhardt, N. Fratzl-Zelman, P. Roschger, S. Rammelt, K.P. Günther, L.C. Hofbauer, Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. Am. J. Physiol. Endocrinol. Metab. 301, E1220–E1228 (2011)PubMedCrossRef
33.
go back to reference N. Erdal, S. Gürgül, S. Kavak, A. Yildiz, M. Emre, Deterioration of bone quality by streptozotocin (STZ)-induced type 2 diabetes mellitus in rats. Biol. Trace Elem. Res. 140, 342–353 (2011)PubMedCrossRef N. Erdal, S. Gürgül, S. Kavak, A. Yildiz, M. Emre, Deterioration of bone quality by streptozotocin (STZ)-induced type 2 diabetes mellitus in rats. Biol. Trace Elem. Res. 140, 342–353 (2011)PubMedCrossRef
34.
go back to reference S. Chakreeyarat, S. Saetung, L.O. Chailurkit, S. Rattanasiri, S. Ditbanjong, N. Chitrapazt, S. Jaovisidha, B. Ongphiphadhanakul, Elevated vitamin D status in postmenopausal women on thiazolidinediones for type 2 diabetes. Endocrine 39, 278–282 (2011)PubMedCrossRef S. Chakreeyarat, S. Saetung, L.O. Chailurkit, S. Rattanasiri, S. Ditbanjong, N. Chitrapazt, S. Jaovisidha, B. Ongphiphadhanakul, Elevated vitamin D status in postmenopausal women on thiazolidinediones for type 2 diabetes. Endocrine 39, 278–282 (2011)PubMedCrossRef
35.
go back to reference M. Yamamoto, T. Yamaguchi, K. Nawata, M. Yamauchi, T. Sugimoto, Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J. Clin. Endocrinol. Metab. 97, 1277–1284 (2012)PubMedCrossRef M. Yamamoto, T. Yamaguchi, K. Nawata, M. Yamauchi, T. Sugimoto, Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J. Clin. Endocrinol. Metab. 97, 1277–1284 (2012)PubMedCrossRef
36.
go back to reference L. Sauque-Reyna, M.A. Salcedo-Parra, P.R. Sánchez-Vargas, J.D. Flores-Helguera, C. Badillo-Sánchez, A. Reza-Albarrán, M. Rodríguez-Morán, F. Guerrero-Romero, Bone mineral density in patients with type 2 diabetes. Rev. Invest. Clin. 63, 162–169 (2011)PubMed L. Sauque-Reyna, M.A. Salcedo-Parra, P.R. Sánchez-Vargas, J.D. Flores-Helguera, C. Badillo-Sánchez, A. Reza-Albarrán, M. Rodríguez-Morán, F. Guerrero-Romero, Bone mineral density in patients with type 2 diabetes. Rev. Invest. Clin. 63, 162–169 (2011)PubMed
37.
go back to reference S. Arikan, A. Tuzcu, M. Bahceci, S. Ozmen, D. Gokalp, Insulin resistance in type 2 diabetes mellitus may be related to bone mineral density. J. Clin. Densitom. 15, 186–190 (2012)PubMedCrossRef S. Arikan, A. Tuzcu, M. Bahceci, S. Ozmen, D. Gokalp, Insulin resistance in type 2 diabetes mellitus may be related to bone mineral density. J. Clin. Densitom. 15, 186–190 (2012)PubMedCrossRef
38.
go back to reference N. Ogata, H. Kawaguchi, Involvement of insulin and IGF-1 signaling molecules in bone metabolism. Clin. Calcium 18, 614–622 (2008)PubMed N. Ogata, H. Kawaguchi, Involvement of insulin and IGF-1 signaling molecules in bone metabolism. Clin. Calcium 18, 614–622 (2008)PubMed
39.
go back to reference T. Akune, N. Ogata, K. Hoshi, N. Kubota, Y. Terauchi, K. Tobe, H. Takagi, Y. Azuma, T. Kadowaki, K. Nakamura, H. Kawaguchi, Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J. Cell. Biol. 159, 147–156 (2002)PubMedCrossRef T. Akune, N. Ogata, K. Hoshi, N. Kubota, Y. Terauchi, K. Tobe, H. Takagi, Y. Azuma, T. Kadowaki, K. Nakamura, H. Kawaguchi, Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J. Cell. Biol. 159, 147–156 (2002)PubMedCrossRef
40.
go back to reference W. Zhang, X. Shen, C. Wan, Q. Zhao, L. Zhang, Q. Zhou, L. Deng, Effects of insulin and insulin-like growth factor 1 on osteoblast proliferation and differentiation: differential signalling via Akt and ERK. Cell. Biochem. Funct. 30, 297–302 (2012)PubMedCrossRef W. Zhang, X. Shen, C. Wan, Q. Zhao, L. Zhang, Q. Zhou, L. Deng, Effects of insulin and insulin-like growth factor 1 on osteoblast proliferation and differentiation: differential signalling via Akt and ERK. Cell. Biochem. Funct. 30, 297–302 (2012)PubMedCrossRef
41.
go back to reference M. Cipok, S. Aga-Mizrachi, A. Bak, T. Feurstein, R. Steinhart, C. Brodie, S.R. Sampson, Protein kinase Calpha regulates insulin receptor signaling in skeletal muscle. Biochem. Biophys. Res. Commun. 345, 817–824 (2006)PubMedCrossRef M. Cipok, S. Aga-Mizrachi, A. Bak, T. Feurstein, R. Steinhart, C. Brodie, S.R. Sampson, Protein kinase Calpha regulates insulin receptor signaling in skeletal muscle. Biochem. Biophys. Res. Commun. 345, 817–824 (2006)PubMedCrossRef
42.
go back to reference M.K. Diamond-Stanic, E.M. Marchionne, Critical role of the transient activation of p38 MAPK in the etiology of skeletal muscle insulin resistance induced by low-level in vitro oxidant stress. Biochem. Biophys. Res. Commun. 405, 439–444 (2011)PubMedCrossRef M.K. Diamond-Stanic, E.M. Marchionne, Critical role of the transient activation of p38 MAPK in the etiology of skeletal muscle insulin resistance induced by low-level in vitro oxidant stress. Biochem. Biophys. Res. Commun. 405, 439–444 (2011)PubMedCrossRef
43.
go back to reference Y. Segev, R. Eshet, O. Yakir, N. Haim, M. Phillip, D. Landau, Systemic and renal growth hormone-IGF1 axis involvement in a mouse model of type 2 diabetes. Diabetologia 50, 1327–1334 (2007)PubMedCrossRef Y. Segev, R. Eshet, O. Yakir, N. Haim, M. Phillip, D. Landau, Systemic and renal growth hormone-IGF1 axis involvement in a mouse model of type 2 diabetes. Diabetologia 50, 1327–1334 (2007)PubMedCrossRef
44.
go back to reference J.L. Bailey, B. Zheng, Z. Hu, S.R. Price, W.E. Mitch, Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J. Am. Soc. Nephrol. 17, 1388–1394 (2006)PubMedCrossRef J.L. Bailey, B. Zheng, Z. Hu, S.R. Price, W.E. Mitch, Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J. Am. Soc. Nephrol. 17, 1388–1394 (2006)PubMedCrossRef
45.
go back to reference V.T. Samuel, G.I. Shulman, Mechanisms for insulin resistance: common threads and missing links. Cell 148, 852–871 (2012)PubMedCrossRef V.T. Samuel, G.I. Shulman, Mechanisms for insulin resistance: common threads and missing links. Cell 148, 852–871 (2012)PubMedCrossRef
46.
go back to reference Y. Zhang, B. Zhou, F. Zhang, J. Wu, Y. Hu, Y. Liu, Q. Zhai, Amyloid-β induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 61, 1434–1443 (2012)PubMedCrossRef Y. Zhang, B. Zhou, F. Zhang, J. Wu, Y. Hu, Y. Liu, Q. Zhai, Amyloid-β induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 61, 1434–1443 (2012)PubMedCrossRef
47.
go back to reference O.T. Hardy, M.P. Czech, S. Corvera, What causes the insulin resistance underlying obesity? Curr. Opin. Endocrinol. Diabetes Obes. 19, 81–87 (2012)PubMed O.T. Hardy, M.P. Czech, S. Corvera, What causes the insulin resistance underlying obesity? Curr. Opin. Endocrinol. Diabetes Obes. 19, 81–87 (2012)PubMed
48.
go back to reference A.R. Martins, R.T. Nachbar, R. Gorjao, M.A. Vinolo, W.T. Festuccia, R.H. Lambertucci, M.F. Cury-Boaventura, L.R. Silveira, R. Curi, S.M. Hirabara, Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function. Lipids Health Dis. 11, 30 (2012)PubMedCrossRef A.R. Martins, R.T. Nachbar, R. Gorjao, M.A. Vinolo, W.T. Festuccia, R.H. Lambertucci, M.F. Cury-Boaventura, L.R. Silveira, R. Curi, S.M. Hirabara, Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function. Lipids Health Dis. 11, 30 (2012)PubMedCrossRef
49.
50.
go back to reference D.C. Leitman, S. Paruthiyil, C. Yuan, C.B. Herber, M. Olshansky, M. Tagliaferri, I. Cohen, T.P. Speed, Tissue-specific regulation of genes by estrogen receptors. Semin. Reprod. Med. 30, 14–22 (2012)PubMedCrossRef D.C. Leitman, S. Paruthiyil, C. Yuan, C.B. Herber, M. Olshansky, M. Tagliaferri, I. Cohen, T.P. Speed, Tissue-specific regulation of genes by estrogen receptors. Semin. Reprod. Med. 30, 14–22 (2012)PubMedCrossRef
51.
go back to reference A. Margoni, L. Fotis, A.G. Papavassiliou, The transforming growth factor-beta/bone morphogenetic protein signalling pathway in adipogenesis. Int. J. Biochem. Cell. Biol. 44, 475–479 (2012)PubMedCrossRef A. Margoni, L. Fotis, A.G. Papavassiliou, The transforming growth factor-beta/bone morphogenetic protein signalling pathway in adipogenesis. Int. J. Biochem. Cell. Biol. 44, 475–479 (2012)PubMedCrossRef
52.
go back to reference P. Magni, E. Dozio, E. Galliera, M. Ruscica, M.M. Corsi, Molecular aspects of adipokine-bone interactions. Curr. Mol. Med. 10, 522–532 (2010)PubMed P. Magni, E. Dozio, E. Galliera, M. Ruscica, M.M. Corsi, Molecular aspects of adipokine-bone interactions. Curr. Mol. Med. 10, 522–532 (2010)PubMed
Metadata
Title
Altered gene expression involved in insulin signaling pathway in type II diabetic osteoporosis rats model
Authors
Baoxin Li
Yan Wang
Yan Liu
Jianxia Ma
Yukun Li
Publication date
01-02-2013
Publisher
Springer US
Published in
Endocrine / Issue 1/2013
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9757-1

Other articles of this Issue 1/2013

Endocrine 1/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.